NAV
17.16(0.76%)Fund Size (CR)
₹1,936.05Expense Ratio
2.07Scheme Type
Active FundValue Research
Min. investment
₹100Minimum Additional Investment
₹100Minimum SIP Investment
₹100Minimum Withdrawal
₹100Exit Load
1%Return Since Launch
33.23%
- 3M
- 6M
- 1Y
- 3Y
- All
Basic Details
Scheme Manager
Nikhil Mathur
Bench Mark
BSE Healthcare TRI
Type
OPEN
Lumpsum Returns
| Period Invested For | ₹10,000 Invested on | Latest Value | Absolute Returns | Annualised Returns | Category Avg | Rank within Category |
|---|---|---|---|---|---|---|
| 1 Week | 4 August 2025 | 9812.70 | -1.87% | - | -0.88% | 779/908 |
| 1 Month | 11 July 2025 | 9912.10 | -0.88% | - | -2.18% | 200/880 |
| 3 Month | 9 May 2025 | 10854.90 | 8.55% | - | 6.29% | 193/864 |
| 6 Month | 11 February 2025 | 10919.64 | 9.20% | - | 8.11% | 359/832 |
| 1 Year | 9 August 2024 | 11329.43 | 13.29% | 13.29% | 0.32% | 50/717 |
| 3 Year | - | - | 0% | - | 19.02% | -/- |
| 5 Year | - | - | 0% | - | 22.68% | -/- |
| Since Inception | 4 October 2023 | 17027.00 | 70.27% | 33.23% | 12.52% | 7/908 |
Note: Lumpsum Returns since Inception Date.
SIP Returns
| Period Invested For | ₹10,000 Invested on | Investments | Latest Value | Absolute Returns | Annualised Returns |
|---|---|---|---|---|---|
| 1 Year | 2 September 2024 | 1,20,000 | 127420.39 | 6.18% | 6.18% |
| 3 Year | - | - | - | - | - |
| 5 Year | - | - | - | - | - |
| 10 Year | - | - | - | - | - |
Note: SIP Returns since Inception Date.
Tax Treatment
If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 10%, if your total long term capital gain exceeds 1 lakh. Any cess/surcharge is not included.If sold before 1 year from purchase date, short term capital gain tax will be applicable. Current tax rate is 15%. Any cess/surcharge is not included in the 15%.
Mutual Funds Calculator
- Investment type
- Scheme based
- SIP
- Lumpsum
Invested Amount
₹25,000
Estimated Returns
₹19,059
76%
Returns
Future value of your investment
₹44,059
Risk Ratios
4.86%
Standard Deviation
0.73%
Beta
1.78%
Sharpe Ratio
0.10%
Treynor's Ratio
23.20%
Jension's Alpha
Asset Allocation
Sector Allocation
Top 10 stock holding in portfolio
| Stock Invested in | % of Total Holdings | Quantity | Value (Cr) | Asset Type | Segment |
|---|---|---|---|---|---|
| Sun Pharma.Inds. | 10.97% | 1244634 | 212.42 | Equity | Pharmaceuticals |
| Divi's Lab. | 8.81% | 258490 | 170.49 | Equity | Pharmaceuticals |
| Glenmark Pharma. | 7.42% | 672796 | 143.58 | Equity | Pharmaceuticals |
| Cipla | 6.33% | 788343 | 122.56 | Equity | Pharmaceuticals |
| Lupin | 5.98% | 599725 | 115.69 | Equity | Pharmaceuticals |
| Ipca Labs. | 4.37% | 574492 | 84.67 | Equity | Pharmaceuticals |
| Torrent Pharma. | 3.88% | 200598 | 75.06 | Equity | Pharmaceuticals |
| Krishna Institu. | 3.82% | 984676 | 73.97 | Equity | Healthcare |
| Laurus Labs | 3.64% | 806343 | 70.50 | Equity | Pharmaceuticals |
| ERIS Lifescience | 3.55% | 381673 | 68.66 | Equity | Pharmaceuticals |
Peer Comparison
| Scheme Name | Value Research | Asset Size (Cr) | 1M | 3M | 6M | 1Y | 3Y |
|---|---|---|---|---|---|---|---|
| Nippon India Taiwan Equity Fund - Direct (G) | 351.43 | 9.27% | 33.03% | 23.45% | 47.70% | 29.15% | |
| Nippon India Taiwan Equity Fund - Direct (IDCW) | 351.43 | 9.27% | 33.03% | 23.45% | 47.70% | 29.15% | |
| Aditya Birla SL International Equity Fund - Direct (G) | 229.26 | 4.85% | 12.57% | 16.37% | 30.62% | 14.02% | |
| Aditya Birla SL International Equity Fund - Direct (IDCW) | 229.26 | 4.85% | 12.57% | 16.37% | 30.62% | 14.02% | |
| Nippon India Japan Equity Fund - Direct (G) | 273.12 | 7.33% | 10.39% | 11.46% | 22.76% | 15.77% |
List of Schemes under HDFC Mutual Fund
News
HDFC MF announces Income Distribution cum capital withdrawal (IDCW) under its scheme
HDFC Mutual Fund has announced 25 July 2025 as the record date for declaration of IDCW in the following schemes. The proposed IDCW on the face value of Rs 10 per unit will be:HDFC Balanced Advantage Fund:
Regular Plan ' IDCW: 0.250
Direct Plan ' IDCW: 0.250
Powered by Capital Market - Live News
HDFC MF announces Income Distribution cum Capital Withdrawal (IDCW) under under its schemes
HDFC Mutual Fund has announced 24 July 2025 as the record date for declaration of Income Distribution cum Capital Withdrawal (IDCW) on the face value of Rs 10 per unit under the regular plan IDCW & monthly IDCW option and direct plan IDCW & monthly IDCW option of HDFC Arbitrage Fund. The amount of distribution (Rs per unit) will be:HDFC Arbitrage Fund ' Wholesale Plan ' Regular Plan ' Normal IDCW Option (Payout & Reinvestment): 0.050
HDFC Arbitrage Fund ' Wholesale Plan ' Direct Plan ' Normal IDCW Option (Payout & Reinvestment): 0.050
HDFC Arbitrage Fund ' Wholesale Plan ' Regular Plan ' Monthly IDCW Option (Payout & Reinvestment): 0.050
HDFC Arbitrage Fund ' Wholesale Plan ' Direct Plan ' Monthly IDCW Option (Payout & Reinvestment): 0.050
Powered by Capital Market - Live News
HDFC Mutual Fund launches HDFC Innovation Fund
HDFC Asset Management Company, one of India's leading mutual fund houses, has launched HDFC Innovation Fund, an open-ended, actively managed equity scheme aimed at investing in companies embracing innovative strategies across sectors.The New Fund Offer (NFO) opened on June 27, 2025 and will close on July 11, 2025.
The fund seeks to capitalise on India's rapidly growing innovation ecosystem, driven by technological advancements, a vibrant startup culture, rising digital adoption, and government-led initiatives. HDFC Innovation Fund aims to identify and invest in companies that are either pioneers or early adopters of new technologies, offering investors a chance to participate in India's ongoing transformation.
The scheme will allocate at least 80% of its net assets to equity and equity-related instruments, focusing on three key areas: product innovation, process innovation, and business model innovation. It will adopt a bottom-up stock selection strategy, ensuring diversification across sectors and market caps while targeting high-quality companies expected to outperform their industry peers.
Investors can enter the fund with a minimum investment of Rs 100 during both the NFO period and after the scheme reopens for continuous purchase and sale. It offers both direct and regular plans, with growth and income distribution cum capital withdrawal options. An exit load of 1% will be charged if units are redeemed within one month from allotment; no exit load will apply thereafter. The fund will be benchmarked against the NIFTY 500 Total Returns Index.
Navneet Munot, managing director and chief executive officer, HDFC Asset Management Company, said, At HDFC Mutual Fund, we continue to expand our investment offerings to fulfil our mission to be the wealth creator for every Indian and to meet the evolving needs of our investors. With our experienced investment team and research-driven approach, we aim to capture the long-term wealth creation potential of innovation-focused businesses.
The fund will be managed by Amit Sinha, fund manager and senior equity analyst, HDFC Asset Management Company. Commenting on the launch, Amit said, The Indian Economy is at an exciting juncture with key pillars supporting the innovation ecosystem. HDFC Innovation Fund offers investors an opportunity to participate in India's innovation-led growth story by gaining exposure to companies adopting transformative strategies across products, processes, and business models.
Powered by Capital Market - Live News
Fund House Details & Investment Objective
Date of Incorporation
14 September 2023
Total AUM (Cr)
₹1936.05
HDFC Pharma and Healthcare Fund - Regular (G) is an Sectoral / Thematic-oriented fund from the renowned AMC, HDFC Mutual Fund. Launched in 14 September 2023, this fund is managed by Nikhil Mathur. With assets under management (AUM) worth ₹1,936.05 (Cr), as of 12 August 2025, HDFC Pharma and Healthcare Fund - Regular (G) is categorized as a Sectoral / Thematic within its segment. The fund has generated a return of 33.23% since its launch.
The current NAV of HDFC Pharma and Healthcare Fund - Regular (G) is ₹17.16, as on 12 August 2025. The fund's benchmark index is BSE Healthcare TRI. You can invest in HDFC Pharma and Healthcare Fund - Regular (G) via both lumpsum and SIP modes. The minimum SIP amount in the fund is ₹100 while the minimum lumpsum investment is ₹100.
Being an open-ended fund, you can exit the fund anytime subject to applicable exit loads:
In respect of each purchase/Switch-in of units, an Exit load of 1% is payable if units are redeemed/switched-out within 30 days from the date of allotment. No Exit Load is payable if units are redeemed / switched-out after 30 days from the date of allotment. The fund has generated undefined% and undefined% CAGR in the last 3 and 5 years respectively.
The fund aims to provide long-term capital appreciation and growth, by investing in a mix of financial instruments 98.20% in Equity, 2.09% in Debt and -0.29% in cash and cash equivalents.
The top 5 sectors the fund invests in are: 71.84% in Pharmaceuticals & Biotech, 21.02% in Healthcare Services, 3.05% in Debt, 1.76% in Healthcare Equipment & Su, 1.61% in Others